Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:ITCI NASDAQ:NAMS NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$197.94-0.6%$180.96$111.09▼$203.59$12.12B0.39490,452 shs273,080 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ANAMSNewAmsterdam Pharma$25.24+2.5%$22.54$14.06▼$27.29$2.84B-0.01869,674 shs661,191 shsROIVRoivant Sciences$12.54+1.2%$11.51$8.73▼$13.06$8.53B1.155.74 million shs5.21 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.52%+1.27%+14.14%+14.66%+43.85%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+79.95%NAMSNewAmsterdam Pharma+2.41%-2.22%+15.74%+27.02%+50.00%ROIVRoivant Sciences+3.86%+4.65%+9.55%+10.53%+1.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.4505 of 5 stars3.54.00.00.04.11.70.6ITCIIntra-Cellular Therapies0.9353 of 5 stars1.10.00.04.50.01.70.6NAMSNewAmsterdam Pharma3.821 of 5 stars4.51.00.00.04.05.00.0ROIVRoivant Sciences3.1694 of 5 stars3.62.00.00.04.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$244.3623.45% UpsideITCIIntra-Cellular Therapies 2.20Hold$118.00-10.52% DownsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5564.60% UpsideROIVRoivant Sciences 3.20Buy$16.3830.63% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, ITCI, ROIV, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$227.00 ➝ $230.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$45.008/19/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$254.00 ➝ $260.008/8/2025ASNDAscendis Pharma A/SCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.008/8/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$243.00 ➝ $290.008/8/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$210.00 ➝ $230.008/8/2025ASNDAscendis Pharma A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$306.00 ➝ $307.008/8/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.008/8/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$490.75M24.69N/AN/A($3.48) per share-56.88ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44NAMSNewAmsterdam Pharma$45.56M62.40N/AN/A$6.91 per share3.65ROIVRoivant Sciences$29.05M294.66N/AN/A$7.05 per share1.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A824.73N/A-54.94%N/A-24.31%11/13/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest NAMS, ITCI, ROIV, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69ITCIIntra-Cellular TherapiesN/A7.667.51NAMSNewAmsterdam PharmaN/A21.0821.08ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AITCIIntra-Cellular Therapies92.33%NAMSNewAmsterdam Pharma89.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%ITCIIntra-Cellular Therapies2.60%NAMSNewAmsterdam Pharma20.84%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableNAMS, ITCI, ROIV, and ASND HeadlinesRecent News About These CompaniesRoivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients2 hours ago | globenewswire.comPDT Partners LLC Buys 60,460 Shares of Roivant Sciences Ltd. $ROIVSeptember 3 at 8:13 AM | marketbeat.comTroluce Capital Advisors LLC Invests $7.19 Million in Roivant Sciences Ltd. $ROIVSeptember 3 at 7:51 AM | marketbeat.comCitigroup Initiates Coverage of Roivant Sciences (ROIV) with Buy RecommendationSeptember 3 at 6:30 AM | msn.comCaption Management LLC Acquires 106,323 Shares of Roivant Sciences Ltd. $ROIVSeptember 3 at 6:29 AM | marketbeat.comRoivant Sciences Ltd. $ROIV Shares Sold by Corebridge Financial Inc.September 2 at 4:57 AM | marketbeat.comNorthern Trust Corp Has $33.31 Million Stock Holdings in Roivant Sciences Ltd. $ROIVSeptember 1 at 3:51 AM | marketbeat.comSB Investment Advisers UK Ltd. Sells 204,819 Shares of Roivant Sciences Ltd. $ROIVAugust 31 at 7:00 AM | marketbeat.comRoivant Sciences Ltd. $ROIV Shares Sold by Rafferty Asset Management LLCAugust 31 at 5:22 AM | marketbeat.comAffinity Asset Advisors LLC Acquires Shares of 150,000 Roivant Sciences Ltd. $ROIVAugust 28, 2025 | marketbeat.comCandriam S.C.A. Invests $276,000 in Roivant Sciences Ltd. $ROIVAugust 27, 2025 | marketbeat.comLe PDG d'Immunovant cède pour 1,17 million de dollars d'actions Roivant SciencesAugust 25, 2025 | zonebourse.comZBlackBarn Capital Partners LP Acquires 625,000 Shares of Roivant Sciences Ltd. $ROIVAugust 25, 2025 | marketbeat.comEric Venker Sells 100,000 Shares of Roivant Sciences (NASDAQ:ROIV) StockAugust 23, 2025 | insidertrades.comRep. Lisa C. McClain Purchases Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)August 23, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Position in Roivant Sciences Ltd. $ROIVAugust 22, 2025 | marketbeat.comNuveen LLC Takes $31.99 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)August 19, 2025 | marketbeat.comSwiss National Bank Sells 22,100 Shares of Roivant Sciences Ltd. $ROIVAugust 19, 2025 | marketbeat.comTimeless Rajeev Ram wins Cincinnati Open, Vivek Ramaswamy recalls playing with USA starAugust 18, 2025 | msn.comInvesco Ltd. Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)August 18, 2025 | marketbeat.comCitigroup Inc. Acquires 81,482 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)August 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, ITCI, ROIV, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$197.94 -1.23 (-0.62%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$25.24 +0.61 (+2.48%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Roivant Sciences NASDAQ:ROIV$12.54 +0.15 (+1.17%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
